EDIT vs NTLA
Editas Medicine (EDIT) and Intellia Therapeutics (NTLA) are genome research companies in Cambridge, MA founded just after the advent of CRISPR technology in 2012. They develop innovative treatments with gene editing, with a high concentration of Ph.D. and M.D. employees working in multiple collaborations with large pharmaceutical companies that provide additional capital and resources. Fiercely in competition with one another, they seek niches to call their own. NTLA has focused slightly more on blood-related disorders while EDIT has primarily taken aim at cancer and neurological disorders. Both have only reported negative earnings while they strive to bring viable treatments to market. Genome research has been a contentious topic for some time, so political climate is a big variable, and news events cause wild swings in the prices of both. NTLA’s market cap grew significantly in 2021, but it remains to be seen if this will give it a lasting advantage over EDIT.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
EDIT’s FA Score shows that 1 FA rating(s) are green whileNTLA’s FA Score has 1 green FA rating(s).
- EDIT’s FA Score: 1 green, 4 red.
- NTLA’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
EDIT’s TA Score shows that 5 TA indicator(s) are bullish while NTLA’s TA Score has 5 bullish TA indicator(s).
- EDIT’s TA Score: 5 bullish, 5 bearish.
- NTLA’s TA Score: 5 bullish, 3 bearish.
Price Growth
EDIT (@Biotechnology) experienced а +15.32% price change this week, while NTLA (@Biotechnology) price change was +6.79% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +7.02%. For the same industry, the average monthly price growth was -13.21%, and the average quarterly price growth was -24.46%.
Reported Earning Dates
EDIT is expected to report earnings on Jul 30, 2025.
NTLA is expected to report earnings on Jul 31, 2025.
Industries' Descriptions
@Biotechnology (+7.02% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| EDIT | NTLA | EDIT / NTLA | |
| Capitalization | 107M | 748M | 14% |
| EBITDA | -233.11M | -523.98M | 44% |
| Gain YTD | 0.787 | -37.993 | -2% |
| P/E Ratio | N/A | N/A | - |
| Revenue | 32.3M | 57.9M | 56% |
| Total Cash | 270M | 602M | 45% |
| Total Debt | 35M | 210M | 17% |
EDIT | NTLA | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 7 | 59 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 21 Undervalued | 25 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 95 | 91 | |
PRICE GROWTH RATING 1..100 | 65 | 93 | |
P/E GROWTH RATING 1..100 | 100 | 100 | |
SEASONALITY SCORE 1..100 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
EDIT's Valuation (21) in the Biotechnology industry is in the same range as NTLA (25). This means that EDIT’s stock grew similarly to NTLA’s over the last 12 months.
EDIT's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as NTLA (100). This means that EDIT’s stock grew similarly to NTLA’s over the last 12 months.
NTLA's SMR Rating (91) in the Biotechnology industry is in the same range as EDIT (95). This means that NTLA’s stock grew similarly to EDIT’s over the last 12 months.
EDIT's Price Growth Rating (65) in the Biotechnology industry is in the same range as NTLA (93). This means that EDIT’s stock grew similarly to NTLA’s over the last 12 months.
EDIT's P/E Growth Rating (100) in the Biotechnology industry is in the same range as NTLA (100). This means that EDIT’s stock grew similarly to NTLA’s over the last 12 months.
| EDIT | NTLA | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 86% | 2 days ago 84% |
| Stochastic ODDS (%) | 2 days ago 88% | 2 days ago 90% |
| Momentum ODDS (%) | 2 days ago 77% | 2 days ago 80% |
| MACD ODDS (%) | 2 days ago 81% | 2 days ago 71% |
| TrendWeek ODDS (%) | 2 days ago 78% | 2 days ago 79% |
| TrendMonth ODDS (%) | 2 days ago 89% | 2 days ago 90% |
| Advances ODDS (%) | 4 days ago 77% | 5 days ago 78% |
| Declines ODDS (%) | 11 days ago 89% | 3 days ago 87% |
| BollingerBands ODDS (%) | 2 days ago 88% | 2 days ago 84% |
| Aroon ODDS (%) | 2 days ago 90% | 2 days ago 90% |
